IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3648
Positioning
Market Dominance
Services
Computer Software
$68.1B
Michael Intrator
CoreWeave powers the creation and delivery of the intelligence that drives innovation. We are the AI Hyperscaler™ driving the AI revolution. Our CoreWeave Cloud Platform consists of our proprietary software and cloud services that deliver the software and software intelligence needed to manage complex AI infrastructure at scale. Our principal executive offices are located in Livingston, NJ 07039.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = CRWV ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 17.1% | 10.3% | 35.5% | 14.6% | 10.1% | 105.2% | 0.0% | 41.0x | $244M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.1% | 8.3% | 45.7% | 8.5% | 6.2% | 28.1% | 0.0% | 0.0x | $736M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 0.0% | - | 97.4% | 58.0% | 37.4% | - | 8.8% | 264.0x | $2.5B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 15.3% | 5.8% | 100.0% | 6.9% | 5.2% | 15.1% | 0.0% | 24.0x | $1.8B | VS | |
$CRWV CoreWeave, Inc. | 39 | 29 | 35 | 47 | - | 296.0x | -11.4% | -1.3% | 73.0% | 3.8% | -8.1% | 133.7% | 0.0% | 362.0x | $68.1B | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.7% | 2.4% | 64.6% | 4.5% | 2.8% | 8.6% | 0.0% | 0.3x | - | REF |
CoreWeave, Inc. (CRWV) receives a "Avoid" rating with a composite score of 39.2/100. It ranks #3648 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CRWV.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 29 | 15 | +14ALPHA |
| MOMENTUM | 47 | 46 | +1NEUTRAL |
| VALUATION | 35 | 30 | +5NEUTRAL |
| INVESTMENT | 17 | 1 | +16ALPHA |
| STABILITY | 18 | 9 | +9ALPHA |
| SHORT INT | 76 | 90 | -14DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 0.4% vs WACC 8.7% (spread -8.2%)
GM 73% vs sector 65%, OM 4% vs sector 5%
Capital turnover 0.11x, R&D intensity 4.6%
Rev growth 134%
Interest coverage N/A, Net debt/EBITDA 234.1x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate CoreWeave, Inc. (CRWV) as Avoid with a composite score of 39.2/100 at a current price of $99.30. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
CoreWeave, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.2/100 places it at rank #3648 in our full universe.
No Moat
Very High
Poor
Fair Value
Gross margins of 73% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 362% D/E amplifies downside risk.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
CoreWeave, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags CoreWeave, Inc. with an Avoid rating, assigning a composite score of 39.2/100 and 1 out of 5 stars. Ranked #3648 of 7,333 stocks, CRWV falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CRWV's quality score of 29/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -11.4% (sector avg: 5.7%), gross margins of 73.0% (sector avg: 64.6%), net margins of -8.1% (sector avg: 2.8%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 35/100, CRWV appears somewhat expensive relative to its fundamentals. Key valuation metrics include an EV/EBITDA of 295.98x, a P/B ratio of 12.21x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
CoreWeave, Inc.'s investment score of 17/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 133.7% vs. a sector average of 8.6% and a return on assets of -1.3% (sector: 2.4%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CRWV is currently showing below-average momentum at 47/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 133.7% year-over-year, while a beta of 2.28 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
CoreWeave, Inc. registers a low stability score of 18/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.28 and a debt-to-equity ratio of 362.00x (sector avg: 0.3x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
CRWV carries a short interest score of 76/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include high market sensitivity (beta: 2.28), elevated leverage (D/E: 362.00x). At $68.1B market cap (large-cap), CoreWeave, Inc. offers reasonable institutional liquidity.
CoreWeave, Inc. is a large-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #3648 of 7,333 overall (50th percentile). Key comparisons include ROE of -11.4% trailing the 5.7% sector median and operating margins of 3.8% below the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While CRWV currently exhibits a AVOID profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (17) would have the largest impact on the composite score.
EV/EBITDA 2423% ABOVE SECTOR MEDIAN
ROE 298% BELOW SECTOR MEDIAN
Gross Margin 13% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
AMD gave up equity in its deals with Meta and OpenAI. Nvidia shareholders should be glad it doesn't need to go there.
CoreWeave (NasdaqGS:CRWV) is facing multiple securities class action lawsuits alleging misleading statements about its growth and operational capacity. Blue Owl Capital did not secure US$4b in planned financing for a CoreWeave data center project, raising questions about access to capital. The company is contending with skepticism over its debt heavy model, sector wide credit tightening, and new tariffs on advanced AI chips. These issues are converging ahead of a closely watched earnings...
CoreWeave (CRWV) is aiming to raise nearly $8.5 billion from banks, including Morgan Stanley (MS) an
Cathie Wood's Ark Invest added to positions in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday as all three growth stocks trade significantly below their 2025 highs. Figma showed strong Q4 results with 40% revenue growth and improved margins, while CoreWeave benefits from AI infrastructure demand. Recursion faces headwinds after Nvidia exited its stake, though the company remains a clinical-stage AI-driven biotech play.
Billionaire Philippe Laffont, founder of Coatue Management, sold his entire CoreWeave position in Q4 2025 after gaining approximately 80% returns since the company's IPO in March 2025. Simultaneously, he opened a small position in Moderna by purchasing 200,000 shares. Moderna stock surged nearly 50% in January 2026 as the biotech company pivots toward long-term growth through its respiratory vaccine franchise and pipeline candidates in oncology and rare diseases.